Renal Cell Carcinoma in a Transplanted Kidney: Successful Organ-Preserving Procedure

Höppner, Wolfgang; Große, Katharina; Dreikorn, K.

doi:10.1159/000282823

Cited by 22 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 1988 to 2016, a total of 56 studies were found reporting on SRMs in transplanted allograft kidneys . Our literature search yielded one multicenter retrospective case series, 19 single‐institution case series, and 36 case reports.…”

Section: Resultsmentioning

confidence: 99%

Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management

Griffith

Amin

Waingankar

et al. 2017

American Journal of Transplantation

View full text Add to dashboard Cite

The objective of this review is to explore the available literature on solid renal masses (SRMs) in transplant allograft kidneys to better understand the epidemiology and management of these tumors. A literature review using PubMed was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology. Fifty-six relevant studies were identified from 1988 to 2015. A total of 174 SRMs in 163 patients were identified, with a mean tumor size of 2.75 cm (range 0.5-9.0 cm). Tumor histology was available for 164 (94.3%) tumors: clear cell renal cell carcinoma (RCC; 45.7%), papillary RCC (42.1%), chromophobe RCC (3%), and others (9.1%). Tumors were managed by partial nephrectomy (67.5%), radical nephrectomy (19.4%), percutaneous radiofrequency ablation (10.4%), and percutaneous cryoablation (2.4%). Of the 131 patients (80.3%) who underwent nephron-sparing interventions, 10 (7.6%) returned to dialysis and eight (6.1%) developed tumor recurrence over a mean follow-up of 2.85 years. Of the 110 patients (67.5%) who underwent partial nephrectomy, 3.6% developed a local recurrence during a mean follow-up of 3.12 years. The current management of SRMs in allograft kidneys mirrors management in the nontransplant population, with notable findings including an increased rate of papillary RCC and similar recurrence rates after partial nephrectomy in the transplant population despite complex surgical anatomy.

show abstract

Section: Resultsmentioning

confidence: 99%

Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management

Griffith

Amin

Waingankar

et al. 2017

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Characteristics of de novo kidney allograft RCCs is currently unknown. The first case of a de novo tumor arising in a transplanted kidney was reported in 1988 by Scott (7), then 42 cases were described in 35 international publications excluding French reports (4,8–41). These publications were mostly case reports or small series that did not exceed five cases.…”

Section: Discussionmentioning

confidence: 99%

De Novo Kidney Graft Tumors: Results From a Multicentric Retrospective National Study

Tillou

Doerfler

Collon

et al. 2012

American Journal of Transplantation

View full text Add to dashboard Cite

De novo tumors in renal allografts are rare and their prevalence is underestimated. We therefore analyzed renal cell carcinomas arising in renal allografts through a retrospective French renal transplant cohort. We performed a retrospective, multicentric survey by sending questionnaires to all French kidney transplantation centers. All graft tumors diagnosed after transplantation were considered as de novo tumors. Thirty-two centers participated in this study. Seventy-nine tumors were identified among 41 806 recipients (Incidence 0.19%). Patients were 54 men and 25 women with a mean age of 47 years old at the time of diagnosis. Mean tumor size was 27.8 mm. Seventy-four (93.6%), 53 (67%) and 44 tumors (55.6%) were organ confined (T1-2), low grade (G1-2) and papillary carcinomas, respectively. Four patients died of renal cell carcinomas (5%). The mean time lapse between transplantation and RCC diagnosis was 131.7 months. Thirty-five patients underwent conservative surgery by partial nephrectomy (n = 35, 44.3%) or radiofrequency (n = 5; 6.3%). The estimated 5 years cancer specific survival rate was 94%. Most of these tumors were small and incidental. Most tumors were papillary carcinoma, low stage and low grade carcinomas. Conservative treatment has been preferred each time it was feasible in order to avoid a return to dialysis.

show abstract

“…Conversely, sparing surgery means preserving the transplanted kidney and offering a better quality of life, but the patients must continue immunosuppressive therapy and must be closely followed up due to the risk of long-term recurrences in the kidney transplant. Sparing surgery is a possibility, and cases in whom this procedure was preferred are described in the literature [11][12][13][14][15] . However, this pathology being extremely rare, the best therapeutic approach is difficult to define.…”

Section: Discussionmentioning

confidence: 99%

Cancer in Kidney Transplantation

Zani

Simeone²,

Antonelli³

et al. 2008

Urol Int

View full text Add to dashboard Cite

Cancer in the transplanted kidney is rare, and its clinical and surgical management can be controversial. We report 3 cases of cancer in renal transplantation (1 case of renal cell carcinoma and 2 cases of transitional cell carcinoma) and their treatment. Our data and those reported in the literature suggest that these cancers can be treated like a neoplasm in the general population. However, a higher number of cases and longer follow-up periods are necessary to confirm our findings.

show abstract

Renal Cell Carcinoma in a Transplanted Kidney: Successful Organ-Preserving Procedure

Cited by 22 publications

References 1 publication

Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management

Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management

De Novo Kidney Graft Tumors: Results From a Multicentric Retrospective National Study

Cancer in Kidney Transplantation

Contact Info

Product

Resources

About